14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EVAC vs PAII: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, EQV Ventures Acquisition Corp. II (EVAC) is the stronger overall head-to-head candidate over Pyrophyte Acquisition Corp. II (PAII) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Valuation Multiples). EVAC carries a Unified Composite Score of 53.5/100 (HOLD) at $10.38 (N/M Forward P/E, 0.0% operating margin), whereas PAII carries 48.1/100 (HOLD) at $10.39 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVAC vs PAII. Trailing 12-month operating profitability (EVAC 0.0% vs PAII 0.0%) and valuation multiples (EVAC N/M vs PAII N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Shell Companies value chain with $283.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EVAC vs PAII Key Questions & Quantitative Answers
As of Nov 16, 2026, EQV Ventures Acquisition Corp. II (EVAC) is the stronger overall head-to-head candidate over Pyrophyte Acquisition Corp. II (PAII) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Valuation Multiples). EVAC carries a Unified Composite Score of 53.5/100 (HOLD) at $10.38 (N/M Forward P/E, 0.0% operating margin), whereas PAII carries 48.1/100 (HOLD) at $10.39 (N/M Forward P/E, 0.0% operating margin). Technically, EVAC sits in a Neutral phase (RSI 67.2, UNCLASSIFIED options structure) and PAII sits in a Markup phase (RSI 88.0, UNCLASSIFIED options structure).
EVAC and PAII split Growth & Scale metrics: EVAC posts +0.0% YoY revenue growth and -9.8% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PAII at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EVAC generates N/A in USD-normalized revenue versus N/A for PAII. In operating R&D and SG&A reinvestment, EVAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PAII.
EVAC screens cheaper on headline valuation multiples. EVAC trades at N/M Forward P/E, 35.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PAII trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVAC (0.0% ROE) versus PAII (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, EVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 1% Vol realized risk). By comparison, PAII carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.00β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.